DM001
Phase 1Small molecule
DM001 is one of 26 small molecule programs targeting Breast Neoplasms. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Breast Neoplasms
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Verzenio
Eli LillyPhase 3
Abraxane
Bristol-Myers SquibbPhase 3
Keytruda
Merck & Co.Phase 3
Ibrance
PfizerPhase 3
Aromasin
PfizerPhase 3
Perjeta
RochePhase 3
Trodelvy
GileadPhase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Faslodex
FFresenius Kabi USA, LLC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Neoplasms1 trial
A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM001 in Patients With Advanced Solid Tumors
Active, not recruiting·XXadcera Biopharmaceutical (Suzhou) Co., Ltd.·Phase 1·NCT06475937·128 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DM001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details